Avondale Partners Upgrades Haemonetics (HAE) to Market Outperform
More News related to HAE
- Haemonetics Corp. (HAE) Posts Q2 EPS of $0.69, Tops by 4c
- Haemonetics Reports Double Digit Growth in Earnings for Second Quarter Fiscal 2010
- Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
- Haemonetics Sets Date for Second Quarter Fiscal Year 2010 Earnings Release: November 2, 2009
- Don't Miss Out! Two Weeks Left to Register for the 2010 IR Global Rankings
More News related to Upgrades
- DA Davidson Upgrade Lifts Shares of Ameron (AMN) by ~9%
- Sterne Agee Upgrades TrustCo Bank Corp NY (TRST) to Neutral
- optionsXpress (OXPS) Upgraded Mid-Day at BofA, Stock Adds 3% to Today's Gains
- D.A. Davidson Upgrades Columbia Sportswear (COLM) to Buy
- Raymond James Upgrades Assoc Banc-Corp (ASBC) to Strong Buy
Avondale Partners upgrades Haemonetics (NYSE: HAE) from Market Perform to Market Outperform with a $72 price target.
Haemonetics Corporation designs, manufactures, and markets automated blood processing systems and single use consumables for blood donors and surgical patients.
Related Categories
UpgradesStocks Mentioned
+0.27Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
